Diagnostic and therapeutic aspects in the infection by SARS-CoV-2, (COVID-19) in Pediatrics

被引:0
作者
Rodriguez-Herrera, Raymundo [1 ]
Rivera-Diaz, Mauricio [2 ]
Huante-Anaya, Alfonso [3 ]
机构
[1] Inst Nacl Pediat, Dept Med Interna, Ciudad De Mexico, Mexico
[2] Secretaria Salud CD MX, Serv Urgencias, Ciudad De Mexico, Mexico
[3] Inst Nacl Pediat, Ciudad De Mexico, Mexico
来源
ACTA PEDIATRICA DE MEXICO | 2020年 / 41卷 / 06期
关键词
Pathogenicity; Human coronavirus; Respiratory tract; SARS-CoV-2; COVID-19; Pandemic; Paediatric population; CORONAVIRUS; CHILDREN; CHLOROQUINE; PREVENTION; MANAGEMENT;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The high pathogenicity human coronavirus predominantly infects the lower respiratory tract causing fatal pneumonia, as it is the case of the current pandemic due to the SARS-CoV-2 virus denominated COVID-19 illness, to which human beings do not have pre-existing immunity. Since the outbreak, an increasing number of studies had investigated COVID-19 on adults, but epidemiologic and clinic characteristics data on offspring are few, who they seem to develop moderate to mild or silent forms of the illness. Even though the mortality is really low, it does exist the risk that pediatric cases could be underdiagnosed. As mentioned, we had revised and selected the most useful and recent information inside our medical branch about the diagnosis and treatment criteria in order to contribute with the knowledge and tendency of the morbidity and mortality of this pandemic on the pediatric population.
引用
收藏
页码:271 / 285
页数:15
相关论文
共 70 条
[61]  
World Health Organization, SOL CLIN TRIAL COVID
[62]  
World Health Organization, 2020, NAM COR DIS COVID 19
[63]  
World Health Organization, 2020, Clinical Management of COVID-19: Interim Guidance
[64]  
World Health Organization, 2020, Naming the Coronavirus Disease (COVID-19) and the Virus That Causes It, V2
[65]  
World Health Organization, MULT INFL SINDR CHIL
[66]   An Update on Current Therapeutic Drugs Treating COVID-19 [J].
Wu R. ;
Wang L. ;
Kuo H.-C.D. ;
Shannar A. ;
Peter R. ;
Chou P.J. ;
Li S. ;
Hudlikar R. ;
Liu X. ;
Liu Z. ;
Poiani G.J. ;
Amorosa L. ;
Brunetti L. ;
Kong A.-N. .
Current Pharmacology Reports, 2020, 6 (3) :56-70
[67]   Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality [J].
Zhang, Chi ;
Wu, Zhao ;
Li, Jia-Wen ;
Zhao, Hong ;
Wang, Gui-Qiang .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)
[68]   The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China [J].
Zhang, Wen ;
Zhao, Yan ;
Zhang, Fengchun ;
Wang, Qian ;
Li, Taisheng ;
Liu, Zhengyin ;
Wang, Jinglan ;
Qin, Yan ;
Zhang, Xuan ;
Yan, Xiaowei ;
Zeng, Xiaofeng ;
Zhang, Shuyang .
CLINICAL IMMUNOLOGY, 2020, 214
[69]   Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? [J].
Zhang, Yuanyuan ;
Zhong, Yanyan ;
Pan, Lin ;
Dong, Jing .
DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (02) :100-102
[70]   Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [J].
Zhou, Fei ;
Yu, Ting ;
Du, Ronghui ;
Fan, Guohui ;
Liu, Ying ;
Liu, Zhibo ;
Xiang, Jie ;
Wang, Yeming ;
Song, Bin ;
Gu, Xiaoying ;
Guan, Lulu ;
Wei, Yuan ;
Li, Hui ;
Wu, Xudong ;
Xu, Jiuyang ;
Tu, Shengjin ;
Zhang, Yi ;
Chen, Hua ;
Cao, Bin .
LANCET, 2020, 395 (10229) :1054-1062